Study S000727

A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03010475
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 41
Start: 2017-01-05
Primary completion: 2017-06-04
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:Furosemide; DRUG:Rosuvastatin; DRUG:SNAC; DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: EUDRACT_NUMBER:2015-003908-23; OTHER:U1111-1173-8618; NIH:2015

Registered primary outcomes

Area under the furosemide plasma concentration-time curve [day 1, day 7, day 54]
Area under the rosuvastatin plasma concentration-time curve [day 2, day 8, day 55]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008631	Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects. Jordy AB, Clinical pharmacokinetics	2021	Other trial	PMID 33782832 DOI	cites ClinicalTrials.gov:NCT03010475; registry reference DERIVED:33782832